Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of iRadimed stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $101.84, for a total value of $509,200.00. Following the completion of the transaction, the chief executive officer directly owned 2,267,500 shares in the company, valued at $230,922,200. This trade represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

iRadimed Stock Performance

NASDAQ:IRMD opened at $103.89 on Friday. iRadimed Corporation has a fifty-two week low of $47.48 and a fifty-two week high of $104.93. The firm has a market cap of $1.32 billion, a PE ratio of 62.96 and a beta of 1.09. The business has a 50 day moving average price of $95.82 and a 200-day moving average price of $79.41.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, topping the consensus estimate of $0.43 by $0.04. The company had revenue of $21.20 million for the quarter, compared to the consensus estimate of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. Research analysts predict that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Announces Dividend

The company also recently announced a special dividend, which was paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th were issued a dividend of $0.50 per share. The ex-dividend date was Wednesday, December 17th. iRadimed’s dividend payout ratio is currently 41.21%.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IRMD. Sowell Financial Services LLC purchased a new position in shares of iRadimed in the 4th quarter valued at approximately $382,000. USA Financial Formulas bought a new position in iRadimed in the fourth quarter worth $82,000. DAVENPORT & Co LLC bought a new position in iRadimed in the fourth quarter worth $233,000. SG Americas Securities LLC lifted its position in iRadimed by 88.6% during the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock valued at $6,848,000 after buying an additional 33,072 shares during the period. Finally, Tudor Investment Corp ET AL purchased a new position in iRadimed during the third quarter valued at $666,000. Institutional investors own 92.34% of the company’s stock.

Wall Street Analyst Weigh In

IRMD has been the topic of a number of research analyst reports. Zacks Research upgraded iRadimed to a “hold” rating in a report on Tuesday, November 4th. Roth Mkm set a $90.00 price objective on iRadimed in a research report on Friday, October 31st. Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Lake Street Capital reaffirmed a “buy” rating and issued a $100.00 price target on shares of iRadimed in a research note on Monday, November 3rd. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $95.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.